MHRA Class 2 Medicines Recall: Compound Sodium Lactate Solution for Infusion BP (Hartmann’s Solution for infusion) in Viaflo 1000ml (Baxter Healthcare Limited)
MHRA Class 2 Medicines Recall: Compound Sodium Lactate Solution for Infusion BP (Hartmann’s Solution for infusion) in Viaflo 1000ml (Baxter Healthcare Limited)
Drug alert number: EL(25)A/46
Date issued: 28 October 2025
Baxter Healthcare is recalling one batch of Compound Sodium Lactate (Hartmann’s Solution) 1000mL. This is due to a packaging error where some cartons labelled as Hartmann’s Solution may contain Ringer’s Solution 1000mL.
DMRC reference number: DMRC-36821405
Company name:Baxter Healthcare Ltd
Medicine Details
Compound Sodium Lactate Solution for Infusion BP (Hartmann’s Solution for infusion) in Viaflo 1000ml
PL: 00116/0330
Active ingredient: Potassium chloride, sodium chloride, sodium lactate, calcium chloride dihydrate
SNOMED code: 17208011000001109
GTIN: 05413760142524 (Unit), 55413760142529 (Carton)
Affected Lot Batch Numbers:
| Batch No. | Expiry Date | Pack Size | First Distributed |
| 25C11T3B | 29/2/2028 | 1000 ml | 28/4/2025 |
Background
Baxter Healthcare is recalling one batch of Compound Sodium Lactate (Hartmann’s Solution) 1000mL. This is due to a packaging error where some cartons within this batch labelled as Hartmann’s Solution may contain Ringer’s Solution 1000mL. This means the wrong product may be inside the box (mixed product in carton).
Advice for Healthcare Professionals
Stop supplying the above batch immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process.
Baxter Healthcare Ltd can confirm 55,340 packs of this batch have been released and distributed. No related adverse event reports or product quality complaints have been received related to this defect.
View the full alert here.
Advice for Patients
No further action is required by patients as this is a Pharmacy and Wholesaler level recall related to a specific batch of Fucidin 250 mg Tablets.
Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information
For all medical information enquiries and information on this product, please email Medinfo_UKI@baxter.com, or telephone 0800 0260514.
For stock control enquiries please email victoria_franklin@baxter.com, or telephone +44 07825 374866.
